SCHEMBL19656295

SCHEMBL19656295

Cc1cc(C(=O)NC(C)(C)CO)cc(-c2ccc(Cl)cc2)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 4/20 0.46
CNR1 P21554 3/20 0.46
GABRA5 P31644 2/20 0.45
SCN10A Q9Y5Y9 1/20 0.43
ANO1 Q5XXA6 1/20 0.42
NPC1 O15118 3/20 0.42
RAB9A P51151 3/20 0.42
ATM Q13315 1/20 0.42
AKR1C4 P17516 1/20 0.42
AKR1C3 P42330 1/20 0.42
AKR1C2 P52895 1/20 0.42
SHMT1 P34896 1/20 0.40
SHMT2 P34897 1/20 0.40
HPGD P15428 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
POLB P06746 1/20 0.39
MAP4K4 O95819 1/20 0.39
RXRA P19793 2/20 0.39
RXRB P28702 2/20 0.39
L3MBTL1 Q9Y468 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18512788 0.90 L3MBTL1 (0.51) CNR2CNR1SCN10AANO1AKR1C4
SCHEMBL18512933 0.88 SCN10A (0.43) GABRA5SCN10AANO1AKR1C4AKR1C3
SCHEMBL19656304 0.86 ANO1 (0.51) CNR1SCN10AANO1AKR1C4AKR1C3
SCHEMBL18285279 0.86 CNR2 (0.45) CNR2CNR1GABRA5ANO1NPC1
SCHEMBL29727654 0.86 CNR2 (0.45) CNR2CNR1GABRA5SCN10AANO1
SCHEMBL18285323 0.86 CNR2 (0.45) CNR2CNR1GABRA5SCN10AANO1
SCHEMBL29727678 0.86 CNR2 (0.45) CNR2CNR1GABRA5ANO1NPC1
SCHEMBL29727640 0.82 HTT (0.49) CNR2CNR1GABRA5NPC1RAB9A
SCHEMBL18285325 0.82 HTT (0.49) CNR2CNR1GABRA5NPC1RAB9A
SCHEMBL19656298 0.82 SCN10A (0.43) CNR1SCN10AANO1AKR1C4AKR1C3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3464246-B1 PYRAZOL COMPOUNDS AS EAAT3 INHIBITORS HOFFMANN LA ROCHE (CH) 2020-07-08 EP disclosed
US-10457644-B2 Pyrazol compounds as EAAT3 inhibitors HOFFMAN-LA ROCHE INC. (US) 2019-10-29 US disclosed
US-20190119218-A1 PYRAZOL COMPOUNDS AS EAAT3 INHIBITORS HOFFMANN-LA ROCHE INC. (US) 2019-04-25 US disclosed
WO-2017202896-A1 PYRAZOL COMPOUNDS AS EAAT3 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2017-11-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190119218-A1 PYRAZOL COMPOUNDS AS EAAT3 INHIBITORS SLC1A1, SLC1A3, SLC1A2 CNR2 2784/4885CNR1 2073/4885GABRA5 958/4885
US-10457644-B2 Pyrazol compounds as EAAT3 inhibitors SLC1A1, SLC1A3, SLC1A2 CNR2 2784/4885CNR1 2073/4885GABRA5 958/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.